Atlas Ventures | GenomeWeb

Atlas Ventures

The firms announced a deal to identify strategic investments in technology areas within agriculture "to support and complement Monsanto's interests and potential growth areas."

The startup has now raised a total of $26 million in Series A financing to support development of a biomarker-based cancer diagnostic.

The new preliminary prospectus offers for sale around 9.6 million shares by shareholders of the firm. Helicos won't receive any proceeds from the sale.

Short Reads

Premium

Life Technologies, Max Planck Institute for Evolutionary Anthropology, 454 Life Sciences, Applied Biosystems, Baylor College of Medicine, University of Bristol, University of Liverpool, John Innes Centre, Helicos BioSciences, Febit, and more…

Helicos filed the prospectus for 68.4 million shares held by investors who participated in a private placement in December. The firm would receive none of the proceeds from the sale of those shares, if any of them are sold.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.